Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8384471 | 0.92 | CTNNB1 (0.54) | CTNNB1WNT3ACES2ALDH1A1POLB | |
| SCHEMBL1423257 | 0.85 | ALDH1A1 (0.55) | CES2ALDH1A1POLBHDAC3HDAC1 | |
| SCHEMBL2743311 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HDAC1NPC1KMT2ARAB9A | |
| SCHEMBL17134152 | 0.83 | HDAC3 (0.60) | CTNNB1WNT3ACES2ALDH1A1POLB | |
| SCHEMBL27629242 | 0.82 | HDAC3 (0.59) | CTNNB1WNT3ACES2ALDH1A1POLB | |
| SCHEMBL2743418 | 0.82 | CTNNB1 (0.54) | CTNNB1WNT3AALDH1A1F2CYP1A2 | |
| SCHEMBL17134082 | 0.81 | HDAC3 (0.58) | CTNNB1WNT3ACES2ALDH1A1POLB | |
| SCHEMBL2743374 | 0.80 | CES2 (0.57) | CTNNB1WNT3ACES2HDAC3HDAC1 | |
| SCHEMBL4309488 | 0.80 | CES2 (0.57) | CTNNB1WNT3ACES2ALDH1A1POLB | |
| SCHEMBL30786693 | 0.80 | CES2 (0.61) | CES2ALDH1A1POLBHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-10-03 | — | — | US | disclosed |
| US-10196402-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3091012-B1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CENTREXION THERAPEUTICS CORP (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-12-21 | — | — | US | disclosed |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-12-21 | — | — | US | disclosed |
| US-9670222-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-8765949-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765949-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2401276-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
| CN-102333777-A | Nitrogen-containing fused heterocyclic compounds and their use as beta-amyloid production inhibitors | EISAI R&D MAN CO LTD | 2012-01-25 | — | — | CN | disclosed |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2011073154-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CTNNB1 4193/4885WNT3A 2740/4885CES2 2463/4885 |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CTNNB1 4193/4885WNT3A 2740/4885CES2 2463/4885 |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CTNNB1 3991/4885WNT3A 2622/4885CES2 2402/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CTNNB1 4193/4885WNT3A 2740/4885CES2 2463/4885 |
| US-10196402-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CTNNB1 4193/4885WNT3A 2740/4885CES2 2463/4885 |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | CTNNB1 351/4885WNT3A 2804/4885CES2 1619/4885 |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CTNNB1 3991/4885WNT3A 2622/4885CES2 2402/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CTNNB1 4193/4885WNT3A 2740/4885CES2 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.